Veracyte reported $18.02M in Operating Profit for its fiscal quarter ending in September of 2026.





Operating Profit Change Date
Agenus USD 15.05M 656K Mar/2026
Agilent USD 444M 45M Jun/2026
Anika Therapeutics USD 646K 3.88M Dec/2025
Arrowhead Research USD -170.09M 28.83M Jun/2026
Bruker USD 83.5M 13.9M Sep/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Illumina USD 305M 45M Sep/2026
Intrexon USD -60.84M 26.62M Jun/2024
Karyopharm Therapeutics USD -26.76M 8.92M Mar/2026
Laboratory Of America USD 418M 38.7M Sep/2026
Ligand Pharmaceuticals USD 54.53M 2.1M Sep/2026
Myriad Genetics USD -3M 20.3M Dec/2025
Rigel Pharmaceuticals USD 14.06M 13.61M Sep/2024
Roche Holding CHF 11.46B 1.91B Jun/2026
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Siemens EUR 2.97B 227M Sep/2026
Sonic Healthcare AUD 435.76M 193.66M Dec/2024
Thermo Fisher Scientific USD 2.46B 277M Sep/2026
Veracyte USD 18.02M 5.94M Sep/2026
Waters USD -86M 234M Jun/2026